RT Journal
A1 McCune SL, Gockerman JP, Rizzieri DA
T1 MOnoclonal antibody therapy in the treatment of non-hodgkin lymphoma
JF JAMA
JO JAMA
YR 2001
FD September 12
VO 286
IS 10
SP 1149
OP 1152
DO 10.1001/jama.286.10.1149
UL http://dx.doi.org/10.1001/jama.286.10.1149
AB 
Monoclonal antibodies are revolutionizing the treatment of many illnesses.
Some patients with coronary artery disease, Crohn disease, solid organ transplants,
rheumatoid arthritis, or cancer have already experienced benefits from these
engineered proteins. Monoclonal antibodies typically either harness the patient's
own immune system to fight disease or suppress an errant immune system. Table 1 lists the monoclonal antibodies
currently approved by the Food and Drug Administration (FDA); more than 50
others are in active clinical trials around the world. Monoclonal antibodies
are currently used by cardiologists, gastroenterologists, nephrologists, and
rheumatologists as well as oncologists. In this article, we focus on the use
of monoclonal antibodies for the treatment of patients with non-Hodgkin lymphoma
(NHL).